Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health: Steve Krognes

Guardant Health has appointed Steve Krognes to its board of directors. He currently serves as a director at Denali Therapeutics, Gritstone Bio, and RLS Global. He previously served on the board of Corvus Pharmaceuticals.

Before joining Guardant's board, Krognes was the CFO of Denali Therapeutics. Prior to that, he served in a variety of roles at multinational corporations, including CFO at Genentech. He chaired the Genentech Access to Care Foundation and represented Genentech on the board and executive committee of the California Life Science Association. Before that, he worked as global head of mergers and acquisitions at Roche, as an investment banker at Goldman Sachs, as a management consultant at McKinsey & Company, and as a venture capitalist in Scandinavia. Krognes holds an MBA from Harvard Business School and a BS in economics from the Wharton School of the University of Pennsylvania.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.